Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06959121 · ClinicalTrials.gov registry record · NA
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
A NA study of Atrial Fibrillation and Ablation, sponsored by Pulse Biosciences.
- Recruiting
- Registry status
- NA
- Development phase
- 135
- Enrollment target
- 2
- Study locations
NCT06959121 is a NA study of Atrial Fibrillation and Ablation that is actively recruiting participants, run by Pulse Biosciences. The registered enrollment target is 135 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06959121, a NA study of Atrial Fibrillation and Ablation, is actively recruiting participants, sponsored by Pulse Biosciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 135 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.
Conditions Studied
Interventions
- DEVICE CellFX® nsPFA™ Cardiac Surgery System
Study Locations (2)
California
- Adventist Heart Institute: Adventist Health St. Helena - St. Helena
Michigan
- Cardiac Surgery Clinic | Frankel Cardiovascular Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2028-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06959121
The ClinicalTrials.gov registry entry for NCT06959121 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower). The listed sponsor is Pulse Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which CellFX® nsPFA™ Cardiac Surgery System is the first listed.
NCT06959121 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Michigan.
Frequently Asked Questions
What is clinical trial NCT06959121 about?
NCT06959121 is a clinical study titled "CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation". The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.
What is the current status of trial NCT06959121?
This trial is currently recruiting. It is a NA study. The enrollment target is 135 participants. The study started on 2025-10-23. Estimated completion is 2028-12.
What conditions does trial NCT06959121 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Ablation, Maze Procedure, AF.
What interventions are being tested in trial NCT06959121?
The interventions under investigation include: CellFX® nsPFA™ Cardiac Surgery System (DEVICE).
Who is sponsoring clinical trial NCT06959121?
This trial is sponsored by Pulse Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06959121 being conducted?
This trial has 2 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
The CONFORM Pivotal Trial
RECRUITING · NA
-
Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study
RECRUITING · NA
-
The Fourth Left Atrial Appendage Occlusion Study
RECRUITING · NA
-
Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.